SEC Form 4 · accession 0001127602-16-060652
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Simon
Officer — President & CEO
Period of report
Aug 16, 2016
Accepted (ET)
Aug 18, 2016 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance SharesF1 | $34.9959 | Aug 16, 2016 | A | 57,149 | A | Aug 16, 2019 | Dec 31, 2019 | Common Stock | 57,149 | 57,149 | D |
Explanation of responses
- F1This grant was made under the terms of Mr. Simon's Employment Agreement and is the matching grant for his August 4, 2016 open market purchase of Haemonetics Corporation common shares. These Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to companies in the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance during a three year period beginning August 4, 2016. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.